An Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion, Phase 1 Study of ES014 in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ES 014 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Elpiscience Biopharmaceuticals

30 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
22 Dec 2022 According to an Elpiscience Biopharmaceuticals media release, the Center of Drug Evaluation (CDE) has cleared Elpiscience Investigational New Drug Application (IND) for ES014 to initiate the trial.
04 Aug 2022 Planned End Date changed from 30 Oct 2025 to 30 Apr 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com